AbbVie’s partnership with Dare to Dream Project focuses on pediatric leukemia

AbbVie Oncology (NYSE:ABBV) recently joined the Dare to Dream Project, an initiative of the Leukemia & Lymphoma Society (LLS) focused on improving the treatment of cancer patients. The initiative is designed to accelerate the development of novel treatments for pediatric blood cancers.

In the interview, Pooja Hingorani, the medical director of oncology early development at AbbVie, discusses the challenges and opportunities in early drug development for pediatric oncology.

Gauri Sunkersett, the associate medical director of pediatric oncology clinical development, discusses later-stage development. She emphasizes the need for innovative trial designs.

The responses have been lightly edited.

How would you characterize the Dare to Dream Project?

Gauri Sunkersett

Gauri Sunkersett: I think the perfect word to describe the Dare to Dream Project by LLS is “rewarding.” The projec…

Read more
  • 0